Kuros Biosciences: First Procedure in MagnetOS Spinal Fusion Trial

Kuros Biosciences announced that the first patient has been treated in an investigator-led, multicenter study comparing MagnetOs bone graft substitute vs. autologous bone in posterolateral spinal fusion.

The blinded, controlled, randomized multicenter trial is scheduled to enroll 100 patients in the Netherlands. Enrollment began in 2H18.

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us